HCTZ is Superior to Hydralazine for BP Control in This Setting
For a patient already on maximum-dose lisinopril, adding hydrochlorothiazide (HCTZ) is the preferred next step for blood pressure control over hydralazine. This recommendation is based on established guideline-directed therapy and the superior evidence base for thiazide diuretics as second-line agents in hypertension management.
Guideline-Directed Approach
The most recent hypertension guidelines consistently position thiazide-type diuretics as first-line or early add-on therapy for blood pressure control. The 2025 AHA/ACC guideline explicitly states that thiazide-type diuretics, along with ACE inhibitors, ARBs, and CCBs, have demonstrated effective reduction of BP and cardiovascular events in randomized controlled trials, making them the foundation of antihypertensive treatment strategies 1. The 2024 ESC guidelines similarly recommend these drug classes as the basis for treatment 2.
When an ACE inhibitor like lisinopril is already maximized, the logical next step is adding a complementary agent from a different class—specifically a thiazide diuretic or calcium channel blocker 3, 1. The 2017 ACC/AHA guideline reinforces that thiazide diuretics should be used for BP control in combination with ACE inhibitors 4.
Why HCTZ Over Hydralazine
Evidence Base and Efficacy
Direct comparative data shows lisinopril demonstrated superior reductions in both systolic and diastolic blood pressure compared to hydrochlorothiazide in controlled trials 5. However, this comparison was for monotherapy. When used in combination with an ACE inhibitor, HCTZ provides additive blood pressure lowering through complementary mechanisms—the ACE inhibitor blocks the renin-angiotensin system while the diuretic reduces volume 6.
A 2022 study confirmed that the combination of lisinopril and hydrochlorothiazide achieved significant reductions in blood pressure (mean reduction of 32.8 mmHg systolic and 17.1 mmHg diastolic) 7. The fixed-dose combination was particularly effective and well-tolerated 8.
Hydralazine's Limited Role
Hydralazine is explicitly not recommended as a first-line or routine second-line agent for hypertension. The 2017 ACC/AHA guidelines state that hydralazine's "unpredictability of response and prolonged duration of action do not make hydralazine a desirable first-line agent for acute treatment in most patients" 3, 9, 10.
Hydralazine is reserved for specific situations:
- As add-on therapy in heart failure with reduced ejection fraction (HFrEF), particularly in Black patients, when combined with isosorbide dinitrate 11, 4, 12
- As a fourth or fifth-line agent when standard three-drug combinations fail 2
- In hypertensive emergencies (IV form) 3, 9
A 1995 study comparing lisinopril to hydralazine found that while both reduced blood pressure, lisinopril was significantly more effective at reducing nighttime blood pressure and caused regression of left ventricular hypertrophy, whereas hydralazine did not 13. This was attributed to hydralazine's reflex sympathetic activation, which counteracts some of its benefits.
Practical Algorithm
Step 1: Confirm lisinopril is truly at maximum tolerated dose (typically 40 mg daily, though doses up to 80 mg have been studied) 5
Step 2: Add HCTZ 12.5-25 mg daily 11, 14
- Start at 12.5-25 mg once daily
- Can increase to 50 mg daily if needed
- Monitor electrolytes (particularly potassium) and renal function at 1-2 weeks, then periodically
Step 3: If BP remains uncontrolled on lisinopril + HCTZ, add a third agent:
- Long-acting dihydropyridine calcium channel blocker (amlodipine 5-10 mg) is preferred 1, 2
- OR consider switching to chlorthalidone if using HCTZ, as it may provide superior 24-hour BP control 15
Step 4: Only if three-drug combination fails, consider:
- Adding spironolactone 12.5-25 mg daily 11, 2
- Beta-blocker if not already indicated
- Then hydralazine as a fourth or fifth-line option 2
Key Caveats
Avoid hydralazine in patients with:
- Coronary artery disease (reflex tachycardia can worsen ischemia)
- Tachycardia at baseline
- Need for predictable, smooth BP control
Monitor for HCTZ-related issues:
- Hypokalemia (though less likely when combined with ACE inhibitor) 6
- Hyperglycemia, hyperuricemia (though generally well-tolerated)
- Volume depletion in elderly patients
Consider chlorthalidone over HCTZ if 24-hour BP control is suboptimal, as recent meta-analysis shows chlorthalidone provides superior systolic and diastolic BP reduction, particularly at night 15. However, chlorthalidone carries higher risk of hypokalemia.
The combination of lisinopril and HCTZ is well-established, evidence-based, and has complementary mechanisms that reduce side effects (the ACE inhibitor mitigates diuretic-induced hypokalemia) 6. This makes it the clear choice over hydralazine for routine BP management in this clinical scenario.